Optimising treatment of HIV-associated Hodgkin lymphoma

Affiliations

¹ ICH Study Center, Hamburg 20146, Germany; University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany. Electronic address: hoffmann@ich-hamburg.de.
² Red Cross Hospital Munich, University of Munich, Munich, Germany.

Comment

Christian Hoffmann et al. Lancet Haematol. 2023 Aug.

. 2023 Aug;10(8):e563-e564.

doi: 10.1016/S2352-3026(23)00177-1.

¹ ICH Study Center, Hamburg 20146, Germany; University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany. Electronic address: hoffmann@ich-hamburg.de.
² Red Cross Hospital Munich, University of Munich, Munich, Germany.

No abstract available

Conflict of interest statement

We declare no competing interests.

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder RF, Mitsuyasu R, Mounier N, Besson C, Noy A; AIDS Malignancy Consortium; Lymphoma Study Association. Rubinstein PG, et al. Lancet Haematol. 2023 Aug;10(8):e624-e632. doi: 10.1016/S2352-3026(23)00157-6. Lancet Haematol. 2023. PMID: 37532416 Free PMC article. Clinical Trial.